Vivaldi Biosciences Inc.
 |
|
Website |
www.vivaldibiosciences.com |
Sector Group |
Health Care |
Fund Relationship |
Bay City Capital, NGN Capital |
Description |
An early-stage biotechnology company focused on the development of advanced vaccines for prevention of common seasonal influenza and emergent pandemic flu. The Company was formed to commercialize patented technologies developed over the course of a decade by Dr. Peter Palese and Dr. Adolfo-Garcia Sastre at the Mount Sinai School of Medicine (MSSM). Theseinvestigators led teams that reconstructed and studied the pathogenicity of the highly virulent but extinct 1918 pandemic influenza virus. Vivaldi’s technologies provide a comprehensive approach to overcome the major drawbacks of existing flu vaccines. The world market for seasonal influenza vaccines is expected to exceed $4 billion by 2010. Vivaldi’s initial focus is development of a seasonal flu vaccine that provides improved protection for adults age fifty and over, who are among the most vulnerable to flu and its complications, and available vaccines generally have reduced efficacy in this age group.
Originally incubated in San Francisco, CA, Vivaldi Biosciences relocated its headquarters and operations to New York City in the fall of 2008. |